Skip to main content

CVRx, Inc.

corporate_fare Company Profile

CVRx, Inc.

CVRX·NASDAQ·Industrial Applications And Services·CIK 0001235912

CVRx is a commercial-stage medical device company that develops, manufactures, and sells innovative and minimally invasive neuromodulation solutions for patients with cardiovascular disease. Its primary product, Barostim, is the first medical technology approved by the U.S. Food and Drug Administration (FDA) that uses neuromodulation to improve symptoms in heart failure (HF) patients. Barostim is an implantable device that delivers electrical pulses to baroreceptors in the carotid artery wall. This counteracts decreased baroreceptor signaling, which otherwise creates an imbalance in the brain's Autonomic Nervous System (ANS) and leads to excess neurohormones that worsen HF. Barostim provides Baroreflex Activation Therapy (BAT, or Barostim Therapy), which connects the cardiovascular system to the ANS. This therapy works alongside pharmaceutical neurohormonal blockade, or Guideline Directed Medical Therapy (GDMT), by increasing baroreceptor signaling to reduce HF symptoms. Barostim received FDA Breakthrough Device designation and is FDA-approved for HF patients in the U.S. The company estimates its total market opportunity for HFrEF in the U.S. to be $10.5 billion based on a prevalence model, and an annual market opportunity of $2.4 billion in the U.S. using an incidence-based model. Approximately 64 million people worldwide suffer from HF, including about 6.7 million in the U.S.

CVRx, Inc. (NASDAQ:CVRX) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 24 items for CVRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 14 rated 8 or above. Recent SEC coverage for CVRX spans 10-Q, 8-K, SCHEDULE 13D/A, SCHEDULE 13D.

Recent high-impact activity:

  • CVRx 10-Q Discloses DOJ False Claims Act Probe Alongside $58.7M Cash and Widening Q3 Loss
  • CVRx Cuts 2026 Revenue Guidance to $56-57M as Q3 Revenue Falls 6%
  • CVRx Cuts Full-Year Revenue Guidance After Q3 Sales Slip 6%
  • Activist Jorey Chernett Exits CVRx After Selling Entire 5.5% Stake
  • CVRx Appoints John Landry as CFO with $500K Salary and 0.80% Equity Grant

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$56.65M
Net Income
-$53.31M
Diluted EPS
-$2.04
Op. Cash Flow
-$40.17M
Free Cash Flow
-$40.75M
Gross Profit
$48.34M
Operating Income
-$51.27M
Cash & Equivalents
$75.71M
Total Debt
$49.51M
Debt / Equity
1.26×
Net Margin
-94.1%
Shares Outstanding
26.31M sh
Source: 10-K · filed 2026-02-13 · accession 0001104659-26-014708

Short Interest & Short Volume

5.33 days to cover

FINRA reported short interest of 1,819,086 shares in CVRX as of the October 30, 2026 settlement, a 14.9% decrease from the prior period — about 5.3 days to cover at its recent average daily volume. On November 20, 2026, 62.5% of CVRX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,819,086 shares as of October 30, 2026
Change vs prior period▼ 14.9%
Days to cover5.33 at avg daily volume of 341,489
Daily short volume (FINRA facilities)62.5% of 241,583 shares on November 20, 2026
5-day average short volume64.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with C →
$0.5012 +0.04% today
52-week range · as of 2026-11-05 $0.5012 – $10.63
Market cap
$14.27M
Volume
520.7K (0.7× avg)
3-mo avg 712.7K
Live data · 2026-11-22 01:53 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CVRX - Latest Insights

CVRX
Nov 05, 2026, 4:17 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.47
Real-time Price: $0.5012 info
Change: -$0.9688 (-66%) info
Market Cap: $14.271M info
CVRX
Nov 05, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.47
Real-time Price: $0.5012 info
Change: -$0.9688 (-66%) info
Market Cap: $14.271M info
CVRX
Nov 05, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.47
Real-time Price: $0.5012 info
Change: -$0.9688 (-66%) info
Market Cap: $14.271M info
CVRX
Oct 02, 2026, 9:30 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $1.53
Real-time Price: $0.5012 info
Change: -$1.03 (-67%) info
Market Cap: $14.271M info
CVRX
Sep 21, 2026, 4:13 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.97
Real-time Price: $0.5012 info
Change: -$2.47 (-83%) info
Market Cap: $14.271M info
CVRX
Aug 24, 2026, 8:00 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $3.12
Real-time Price: $0.5012 info
Change: -$2.62 (-84%) info
Market Cap: $14.271M info
CVRX
Aug 24, 2026, 8:30 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $2.84
Real-time Price: $0.5012 info
Change: -$2.34 (-82%) info
Market Cap: $14.271M info
CVRX
Aug 14, 2026, 3:42 PM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $3.13
Real-time Price: $0.5012 info
Change: -$2.63 (-84%) info
Market Cap: $14.271M info
CVRX
Aug 11, 2026, 7:09 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.38
Real-time Price: $0.5012 info
Change: -$1.88 (-79%) info
Market Cap: $14.271M info
CVRX
Aug 07, 2026, 3:15 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $3.39
Real-time Price: $0.5012 info
Change: -$2.89 (-85%) info
Market Cap: $14.271M info
CVRX
Aug 06, 2026, 4:48 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $4.40
Real-time Price: $0.5012 info
Change: -$3.90 (-89%) info
Market Cap: $14.271M info
CVRX
Aug 06, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.37
Real-time Price: $0.5012 info
Change: -$4.87 (-91%) info
Market Cap: $14.271M info
CVRX
Jun 09, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.47
Real-time Price: $0.5012 info
Change: -$4.97 (-91%) info
Market Cap: $14.271M info
CVRX
May 12, 2026, 8:00 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $6.90
Real-time Price: $0.5012 info
Change: -$6.40 (-93%) info
Market Cap: $14.271M info
CVRX
May 11, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.90
Real-time Price: $0.5012 info
Change: -$6.40 (-93%) info
Market Cap: $14.271M info
CVRX
May 11, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $6.90
Real-time Price: $0.5012 info
Change: -$6.40 (-93%) info
Market Cap: $14.271M info
CVRX
May 04, 2026, 4:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $7.80
Real-time Price: $0.5012 info
Change: -$7.29 (-94%) info
Market Cap: $14.271M info
CVRX
Apr 13, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.09
Real-time Price: $0.5012 info
Change: -$6.59 (-93%) info
Market Cap: $14.271M info
CVRX
Apr 13, 2026, 8:03 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $7.09
Real-time Price: $0.5012 info
Change: -$6.59 (-93%) info
Market Cap: $14.271M info
CVRX
Feb 13, 2026, 8:00 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $5.70
Real-time Price: $0.5012 info
Change: -$5.20 (-91%) info
Market Cap: $14.271M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets